company news
2018.07.31 size

on july 31, 2018, hansoh’s punuoan® ( ambrisentan tablets) received nda approval from national medical products administration to launch as a category 4 first-to-market generic under the new classification system for registration of chemical drugs, equivalent to passing the consistency evaluation.

ambrisentan is a highly selective endothelin receptor antagonist for the treatment of patients with pulmonary hypertension with who (world health organization) class ii or iii symptoms.